Click Therapeutics, Inc.

Based in the US, Click Therapeutics, Inc. develops innovative digital therapeutics that combine neuroscience and advanced software to improve patient health outcomes across various mental and physical conditions. Click Therapeutics, Inc. specializes in creating prescription digital therapeutics that serve as adjuncts to traditional pharmacotherapy.

Founded in 2012, the company is headquartered in New York, US. The founders, Bruce Leuchter, David Klein, Michael McAllister, and Wei Zhou, have extensive backgrounds in the health tech industry. In November 2023, Click Therapeutics successfully secured USD 20 mn in VENTURE DEBT funding from HSBC Innovation Banking, contributing to a total of USD 52. 12 mn raised across 10 deals.

Click Therapeutics focuses on patient-centric digital treatments, prominently featuring Click SE™ solutions, which are prescription digital therapeutics aimed at enhancing traditional pharmacotherapy. These solutions address unmet clinical needs in areas such as mental health and migraines, ensuring clinical validation through rigorous trials. The company primarily serves healthcare providers and patients in the US and select international markets. Click Therapeutics operates a revenue model centered on the commercialization of their prescription digital therapeutics, including Click SE™ solutions.

These digital treatments are typically prescribed through partnerships with healthcare providers, utilizing a subscription-based pricing structure. This model enables seamless integration of digital health solutions into patient care plans, fostering sustainable revenue by aligning financial interests with improved patient outcomes. In November 2023, Click Therapeutics, Inc. plans to utilize the recently acquired USD 20 mn in venture debt funding to further develop its business.

The company is focused on expanding its product offerings and market presence, potentially introducing new digital therapeutics. Specific details regarding upcoming product launches and geographic market expansions have yet to be disclosed.